Monday, September 07, 2020 10:05:07 PM
RE
Coronavirus Vaccine Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp, a New York-based clinical-stage biopharmaceutical company, is working to discover, license, acquire and develop small molecules and biologics to treat and prevent human disease.
Its portfolio is primarily made up of central nervous system and immunology product candidates, including vaccines. In the wake of the current pandemic, that has come to include coronavirus (COVID-19) vaccine candidates.
“The second quarter was highlighted by exciting progress for our lead immunology and central nervous system product candidates,” Tonix CEO Seth Lederman said in a recent statement. “We expect to have the first data from animal studies of our lead COVID-19 vaccine candidate, TNX-1800, in the fourth quarter of this year. TNX-1800 is a live attenuated vaccine based on our proprietary horsepox vector system that carries a gene encoding the Spike protein from SARS-CoV-2, the virus that causes COVID-19.”
This summer, Tonix announced research collaborations with Southern Research and Columbia University to study T-cell and antibody immune responses to the coronavirus in healthy volunteers who have recovered from COVID-19 or were exposed but remain asymptomatic.
Recent TNXP News
- Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering • GlobeNewswire Inc. • 03/28/2024 01:32:56 PM
- Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024 • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:05:22 PM
- Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT • GlobeNewswire Inc. • 03/07/2024 02:37:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:06:09 PM
- Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:05:29 PM
- Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:05:37 PM
- Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:08:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:07:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:06:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:05:49 PM
- Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:06:21 PM
- Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM